Latest Ai Technology News

BrainChip Holdings has initiated tape-out for its AKD1500 neuromorphic AI chip, targeting volume production by late Q3 2026 to meet rising demand for ultra-low-power edge AI solutions.

Vinyl Group Ltd reports a striking 190% revenue surge in FY25 and a record Q1 FY26, setting sights on its first EBITDA-positive quarter by mid-2026.

Resonance Health reveals a robust growth strategy targeting $17 million revenue by FY26, powered by AI-enhanced medical imaging and global clinical trial services expansion.

Straker Limited has secured a substantial two-year translation services contract with a major global enterprise, reinforcing its position in AI-driven language solutions.

Webjet Group has completed its acquisition of Locomote Holdings for $23 million, aiming to fast-track its digital business travel platform and reduce development risks. The move aligns with Webjet’s FY30 Strategic Plan to expand its footprint in corporate travel.

dorsaVi has confirmed its RRAM Reflex Platform achieves biological-grade reflexes with sub-microsecond latency and ultra-low energy use, outperforming leading digital edge AI systems by orders of magnitude.

Vection Technologies has agreed to acquire Australian digital transformation firm DXLabs, adding immediate revenue and expanding its footprint across APAC with promising cross-sell opportunities.

Way2VAT is advancing its position as a global leader in digital tax processing through a strategic acquisition and a robust four-pillar growth plan, targeting profitability by 2026 amid expanding market opportunities.

Decidr AI Industries has successfully completed a $20 million placement, positioning itself to accelerate international growth and advance its AI technology platform.

CloudHolter Pty Ltd reported a substantial $39.7 million net loss for FY2025 amid ongoing cash outflows but continues to raise capital through convertible notes as it targets an IPO by year-end.

Artrya Limited has completed the first tranche of its A$75 million placement, raising approximately A$60 million to advance its AI-driven coronary artery disease platform. Eligible shareholders can now participate in a Share Purchase Plan at the same price.

dorsaVi has inked a five-year sales agreement with Select Medical, opening access to over 1,900 US outpatient physical therapy centers for its FDA-approved motion analysis products. This follows a successful 18-month pilot validating clinical benefits in athlete rehabilitation.